BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Efimosfermin alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Efimosfermin alfa\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07358546-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:Efimosfermin alfa: Phase 1 readout est. (NCT07358546)
DESCRIPTION:Efimosfermin alfa\, phase 1\, MASH / NASH.\nStudy: A Study of E
 fimosfermin Alfa in Adults With Hepatic Impairment\nEstimated primary comp
 letion: 13 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07358546
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221188-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221188)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Clinical S
 tudy to Investigate the Safety and Tolerability of Efimosfermin Alfa Injec
 tion in Participants With Known or Suspected F2- or F3-stage MASH\nEstimat
 ed primary completion: 24 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/efimosfermin-alfa#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07221188
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221227-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20280329
DTEND;VALUE=DATE:20280330
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221227)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-
 confirmed F2- or F3-stage MASH\nEstimated primary completion: 29 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 1227
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920043-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Efimosfermin alfa: Phase 2 readout est. (NCT06920043)
DESCRIPTION:Efimosfermin alfa\, phase 2\, MASH / NASH.\nStudy: A Study of E
 fimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensa
 ted) Due to MASH\nEstimated primary completion: 3 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06920043
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791043-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:Efimosfermin alfa: Phase 2 readout est. (NCT07791043)
DESCRIPTION:Efimosfermin alfa\, phase 2.\nStudy: A Study to Investigate the
  Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult P
 articipants With Alcohol-related Liver Disease (ALD)\nEstimated primary co
 mpletion: 11 August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07791043
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704892-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20301016
DTEND;VALUE=DATE:20301017
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07704892)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Study to I
 nvestigate Safety and Efficacy of Efimosfermin Compared With Placebo in Ad
 ult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-a
 ssociated Steatohepatitis (MASH)\nEstimated primary completion: 16 October
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-a
 lfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704892
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701993-6690@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20330623
DTEND;VALUE=DATE:20330624
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07701993)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate the Safety and Efficacy of Efimosfermin Compar
 ed With Placebo in Adult Participants With Compensated Cirrhosis Due to Me
 tabolic Dysfunction-associated Steatohepatitis (MASH)\nEstimated primary c
 ompletion: 23 June 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07701993
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
